TN2014000337A1 - Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status - Google Patents
Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation statusInfo
- Publication number
- TN2014000337A1 TN2014000337A1 TNP2014000337A TN2014000337A TN2014000337A1 TN 2014000337 A1 TN2014000337 A1 TN 2014000337A1 TN P2014000337 A TNP2014000337 A TN P2014000337A TN 2014000337 A TN2014000337 A TN 2014000337A TN 2014000337 A1 TN2014000337 A1 TN 2014000337A1
- Authority
- TN
- Tunisia
- Prior art keywords
- rnf43
- znrf3
- administration
- cancer patient
- wnt signaling
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 102000013814 Wnt Human genes 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 abstract 4
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 abstract 3
- 101000802406 Homo sapiens E3 ubiquitin-protein ligase ZNRF3 Proteins 0.000 abstract 3
- 102000006083 ZNRF3 Human genes 0.000 abstract 3
- 239000000090 biomarker Substances 0.000 abstract 3
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 abstract 1
- 101100091155 Homo sapiens RNF43 gene Proteins 0.000 abstract 1
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 abstract 1
- 101150041027 ZNRF3 gene Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000012224 gene deletion Methods 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940121396 wnt pathway inhibitor Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261604290P | 2012-02-28 | 2012-02-28 | |
| PCT/US2013/027441 WO2013130364A1 (fr) | 2012-02-28 | 2013-02-22 | Sélection de patient atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2014000337A1 true TN2014000337A1 (en) | 2015-12-21 |
Family
ID=47790546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2014000337A TN2014000337A1 (en) | 2012-02-28 | 2014-08-05 | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20150125857A1 (fr) |
| EP (2) | EP3693476B1 (fr) |
| JP (2) | JP6397335B2 (fr) |
| KR (1) | KR20140132712A (fr) |
| CN (1) | CN104302782A (fr) |
| AU (1) | AU2013226323B2 (fr) |
| BR (1) | BR112014020233A2 (fr) |
| CA (1) | CA2864306A1 (fr) |
| CL (1) | CL2014002269A1 (fr) |
| ES (2) | ES2797533T3 (fr) |
| IL (1) | IL233920A0 (fr) |
| MX (1) | MX2014010265A (fr) |
| NZ (1) | NZ627864A (fr) |
| PH (1) | PH12014501930A1 (fr) |
| RU (2) | RU2017120287A (fr) |
| SG (1) | SG11201404492VA (fr) |
| TN (1) | TN2014000337A1 (fr) |
| WO (1) | WO2013130364A1 (fr) |
| ZA (1) | ZA201405553B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2839755A1 (fr) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Frizzled 2 en tant que cible pour des anticorps therapeutiques dans le traitement du cancer |
| ES2769786T3 (es) | 2011-10-14 | 2020-06-29 | Recordati Ag | Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt |
| EP3693476B1 (fr) | 2012-02-28 | 2023-10-18 | Novartis AG | Sélection de patients atteints d'un cancer pour l'administration d'inhibiteurs de la voie de signalisation de wnt au moyen de l'état mutationnel de rnf43 |
| US9713612B2 (en) | 2013-03-12 | 2017-07-25 | Curegenix, Inc. | Compounds for treatment of cancer |
| WO2015145388A2 (fr) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt |
| KR20170010764A (ko) * | 2014-04-21 | 2017-02-01 | 애브비 스템센트알엑스 엘엘씨 | 신규한 항-rnf43 항체 및 사용 방법 |
| LT3204378T (lt) * | 2014-10-08 | 2019-10-25 | Redx Pharma Plc | N-piridinilo acetamido dariniai kaip wnt signalinio kelio inhibitoriai |
| US20160312207A1 (en) * | 2015-04-21 | 2016-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling |
| CA2985813A1 (fr) * | 2015-05-26 | 2016-12-01 | Curegenix Corporation | Biomarqueurs tumoraux et leur utilisation |
| US11993645B2 (en) | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
| US11958891B2 (en) | 2017-01-26 | 2024-04-16 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses thereof |
| WO2019245460A1 (fr) * | 2018-06-21 | 2019-12-26 | National University Of Singapore | Stratification de patients cancéreux hébergeant des mutations oncogènes dans l'ubiquitine ligase e3 rnf43 |
| JP2021530223A (ja) | 2018-07-09 | 2021-11-11 | スロゼン, インコーポレイテッド | 組織特異性Wntシグナル増強分子及びその使用 |
| US20210299233A1 (en) * | 2018-07-12 | 2021-09-30 | The Children's Medical Center Corporation | Method for treating cancer |
| CA3141632A1 (fr) * | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Traitement de densite minerale osseuse reduite avec des inhibiteurs de zinc et doigt ring 3 (znrf3) |
| CN113564249B (zh) * | 2020-04-28 | 2023-06-16 | 中国科学院分子细胞科学卓越创新中心 | CXorf67在判断肿瘤对DNA损伤药物的敏感性中的应用 |
| WO2022104280A1 (fr) | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Molécules d'amélioration de signaux wnt spécifiques du fois et leurs utilisations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2431929T3 (es) | 2001-09-18 | 2013-11-28 | Genentech, Inc. | Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores |
| CN101613406A (zh) * | 2002-06-06 | 2009-12-30 | 肿瘤疗法科学股份有限公司 | 与人结肠癌相关的基因和多肽 |
| ATE500326T1 (de) * | 2002-06-06 | 2011-03-15 | Oncotherapy Science Inc | Gene und proteine mit bezug zu menschlichem kolonkrebs |
| US20040247593A1 (en) * | 2002-10-04 | 2004-12-09 | Regents Of The University Of California, | Methods for treating cancer by inhibiting Wnt signaling |
| US7718364B2 (en) | 2003-03-25 | 2010-05-18 | John Wayne Cancer Institute | DNA markers for management of cancer |
| EP1771207A4 (fr) * | 2004-07-09 | 2009-05-27 | Univ California | Méthodes destinées à traiter le cancer au moyen d'agents inhibant la signalisation de wnt16 |
| JP2008519829A (ja) * | 2004-11-10 | 2008-06-12 | ヒュブレヒト ラボラトリウム | Notch経路活性化の阻害による腸腺腫および/または腺癌の処置 |
| CA2601157A1 (fr) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biomarqueurs predictifs de reponse anticancereuse a des inhibiteurs de kinase de recepteur de facteur de croissance epidermique |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| WO2011004379A1 (fr) * | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions et méthodes de traitement du cancer |
| EP2549399A1 (fr) | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Evaluation d'activité de voie Wnt utilisant un modelage probabilistique d'expression de gène cible |
| ES2769786T3 (es) | 2011-10-14 | 2020-06-29 | Recordati Ag | Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt |
| EP3693476B1 (fr) | 2012-02-28 | 2023-10-18 | Novartis AG | Sélection de patients atteints d'un cancer pour l'administration d'inhibiteurs de la voie de signalisation de wnt au moyen de l'état mutationnel de rnf43 |
| RS60823B1 (sr) | 2015-12-04 | 2020-10-30 | Boehringer Ingelheim Int | Biparatopski polipeptidi koji antagonizuju wnt signalizaciju u tumorskim ćelijama |
-
2013
- 2013-02-22 EP EP20154250.3A patent/EP3693476B1/fr active Active
- 2013-02-22 BR BR112014020233A patent/BR112014020233A2/pt active Search and Examination
- 2013-02-22 AU AU2013226323A patent/AU2013226323B2/en not_active Ceased
- 2013-02-22 KR KR1020147023667A patent/KR20140132712A/ko not_active Abandoned
- 2013-02-22 CN CN201380011506.6A patent/CN104302782A/zh active Pending
- 2013-02-22 US US14/380,776 patent/US20150125857A1/en not_active Abandoned
- 2013-02-22 WO PCT/US2013/027441 patent/WO2013130364A1/fr not_active Ceased
- 2013-02-22 EP EP13707527.1A patent/EP2820151B1/fr active Active
- 2013-02-22 RU RU2017120287A patent/RU2017120287A/ru not_active Application Discontinuation
- 2013-02-22 ES ES13707527T patent/ES2797533T3/es active Active
- 2013-02-22 ES ES20154250T patent/ES2968742T3/es active Active
- 2013-02-22 CA CA2864306A patent/CA2864306A1/fr not_active Abandoned
- 2013-02-22 SG SG11201404492VA patent/SG11201404492VA/en unknown
- 2013-02-22 NZ NZ627864A patent/NZ627864A/en not_active IP Right Cessation
- 2013-02-22 JP JP2014559931A patent/JP6397335B2/ja active Active
- 2013-02-22 RU RU2014139044A patent/RU2636000C2/ru active
- 2013-02-22 MX MX2014010265A patent/MX2014010265A/es unknown
-
2014
- 2014-07-28 ZA ZA2014/05553A patent/ZA201405553B/en unknown
- 2014-07-31 IL IL233920A patent/IL233920A0/en unknown
- 2014-08-05 TN TNP2014000337A patent/TN2014000337A1/fr unknown
- 2014-08-27 CL CL2014002269A patent/CL2014002269A1/es unknown
- 2014-08-27 PH PH12014501930A patent/PH12014501930A1/en unknown
-
2016
- 2016-12-20 US US15/385,088 patent/US20170306409A1/en not_active Abandoned
-
2018
- 2018-06-26 JP JP2018120856A patent/JP2018172408A/ja active Pending
-
2019
- 2019-01-28 US US16/259,419 patent/US20190203301A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018172408A (ja) | 2018-11-08 |
| KR20140132712A (ko) | 2014-11-18 |
| BR112014020233A2 (pt) | 2017-07-04 |
| PH12014501930A1 (en) | 2014-11-24 |
| AU2013226323A1 (en) | 2014-09-11 |
| ES2797533T3 (es) | 2020-12-02 |
| IL233920A0 (en) | 2014-09-30 |
| MX2014010265A (es) | 2015-06-23 |
| CL2014002269A1 (es) | 2014-12-19 |
| ES2968742T3 (es) | 2024-05-13 |
| WO2013130364A1 (fr) | 2013-09-06 |
| EP2820151B1 (fr) | 2020-03-25 |
| SG11201404492VA (en) | 2014-10-30 |
| CN104302782A (zh) | 2015-01-21 |
| JP6397335B2 (ja) | 2018-09-26 |
| US20150125857A1 (en) | 2015-05-07 |
| AU2013226323B2 (en) | 2016-07-14 |
| NZ627864A (en) | 2015-12-24 |
| EP3693476A1 (fr) | 2020-08-12 |
| CA2864306A1 (fr) | 2013-09-06 |
| RU2014139044A (ru) | 2016-04-20 |
| RU2636000C2 (ru) | 2017-11-17 |
| EP3693476B1 (fr) | 2023-10-18 |
| US20190203301A1 (en) | 2019-07-04 |
| HK1199744A1 (en) | 2015-07-17 |
| JP2015511484A (ja) | 2015-04-20 |
| EP2820151A1 (fr) | 2015-01-07 |
| ZA201405553B (en) | 2015-12-23 |
| RU2017120287A (ru) | 2018-11-15 |
| US20170306409A1 (en) | 2017-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501930A1 (en) | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status | |
| Hales et al. | New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia | |
| AU2018256477A1 (en) | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof | |
| EA201500334A1 (ru) | Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него | |
| MX2022000085A (es) | Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad. | |
| NZ736853A (en) | Methods of treating cancer patients with farnesyl transferase inhibitors | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| TN2014000063A1 (en) | Kinase inhibitor polymorphs | |
| BR112014023162A8 (pt) | compostos e métodos para modulação quinase e indicações dos mesmos | |
| MX2014001246A (es) | Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1. | |
| MX2014005800A (es) | Mutaciones del receptor notch humano y su uso. | |
| HK1208470A1 (en) | Biomarkers for use in integrin therapy applications | |
| EP3284481A4 (fr) | Agent induisant la mort cellulaire pour des cellules ayant une mutation du gène braf, agent pour inhiber la prolifération desdites cellules et composition pharmaceutique pour le traitement d'un patient souffrant des effets de la prolifération anormale desdites cellules | |
| WO2015150472A3 (fr) | Nouvelles stratégies de traitement du mélanome | |
| MX2017002364A (es) | Terapia de combinacion para tratamiento de cancer. | |
| MX2014014097A (es) | Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc). | |
| MX2021000133A (es) | Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa. | |
| IN2014MN01944A (fr) | ||
| GB2523211A8 (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
| WO2012109233A3 (fr) | Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein | |
| HRP20180130T1 (hr) | Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras | |
| WO2013103836A3 (fr) | Procédés de traitement du cancer | |
| TH158534A (th) | การเลือกผู้ป่วยมะเร็งสำหรับการดำเนินการให้ของตัวยับยั้งการส่งสัญญาณ wnt โดยการใช้ภาวะการกลายพันธุ์ rnf43 | |
| PT3284481T (pt) | Agente indutor da morte celular para células com mutação do gene braf, agente para inibição da proliferação das referidas células e composição farmacêutica para tratamento de pacientes que sofrem os efeitos da proliferação anormal das referidas células |